Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how Meiji is responding.

CNS Disorders

an image of the nervous system

Modern medicine recognizes a growing number of mental disorders linked to the central nervous system (CNS). Meiji has decades of expertise in this field, launching some of Japan's earliest antidepressants and anti-anxiety drugs, including the first selective serotonin reuptake inhibitor in 1999.  

Therapeutic Areas

  • Schizophrenia

  • Depression

  • Dravet syndrome

  • Insomnia

  • Panic disorder

  • Post-traumatic stress disorder

  • Obsessive-compulsive disorder

  • a photo of a family
  • Our Approach to Rare and Common CNS Disorders

    CNS disorders are on the rise due to factors such as aging, lifestyle changes, and stress. Effectively treating such a wide range of conditions is a challenge for many societies. Meiji Seika Pharma's primary focus is on new treatments for depression and schizophrenia, as well as Dravet syndrome, a rare form of epilepsy of unknown cause. At the same time, the company supplies generic drugs for widespread conditions such as Alzheimer's.

    * Image used for illustration purposes only.

Find out more from our wellness stories

an image of bacteria that cause infections

Hope for Patients with Dravet Syndrome

Read how Meiji Seika Pharma supports patients with Dravet syndrome, a rare form of epilepsy that first appears in infancy.

READ MORE